Company / Cash & Equivalents
Centene Corporation Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$17.9B
FY2025
5-year range
$12.1B / $17.9B
FY2021-FY2025
Trend
+27.2%
vs FY2024
Sector context
#2 of 148
Health Care
What the data says
Among 148 Health Care companies, Centene Corporation is in the top 1% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $3.9B in FY2016 to $17.9B in FY2025.
Based on SEC 10-K filings.
$17.9B in FY2025 with a 5-year CAGR of +10.6%. Ranks 2nd among 148 companies in Health Care.
Improved from $17.2B to $17.9B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +14.0%
- 5-Year CAGR
- +10.6%
- 10-Year CAGR
- -
Sector benchmark
+1420.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +10.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 27.2% year-over-year.
- Ranks #2 out of 148 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.9B | +27.2% |
| FY2024 | $14.1B | -18.2% |
| FY2023 | $17.2B | +42.4% |
| FY2022 | $12.1B | -8.0% |
| FY2021 | $13.1B | +21.5% |
| FY2020 | $10.8B | -10.9% |
| FY2019 | $12.1B | +126.9% |
| FY2018 | $5.3B | +31.2% |
| FY2017 | $4.1B | +3.6% |
| FY2016 | $3.9B | +123.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026